MOLECULAR PARTNERS AG (MOLN)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (3)

NCT #TitlePhaseStatusEnrollment
NCT05673057 Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome PHASE2 Active Not Recruiting 249
NCT07036380 MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma PHASE2 Recruiting 75
NCT07278479 Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Sol... PHASE2 Recruiting 138

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis